Agios Pharma (AGIO) Misses Q4 EPS by 286c

Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($4.23), $2.86 worse than the analyst estimate of ($1.37). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $4.54 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AXT appoints Tracy Liu to its board of directors
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform